GlassScriptPhysician profile
Regina Overton-Barnes
NPI 1912979485
$5,627.76
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,810 · 2022: $1,900 · 2023: $1,727 · 2024: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,801 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.57 |
| Education | $117.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $944.74 | 2021-2023 | Trelegy Ellipta, Nucala, Arexvy |
| United Therapeutics Corporation | $679.60 | 2021-2023 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $674.38 | 2021-2023 | Tezspire, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $645.94 | 2021-2023 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Grifols USA, LLC | $403.93 | 2021-2023 | Prolastin-C Liquid |
| Insmed, INC. | $324.75 | 2021-2023 | Arikayce |
| Genentech USA, INC. | $302.82 | 2021-2023 | Xolair |
| Genzyme Corporation | $193.08 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $158.48 | 2022-2023 | Uptravi, Opsumit |
| Amgen INC. | $135.17 | 2021-2023 | Tezspire |
| Axsome Therapeutics, INC. | $121.82 | 2024 | Auvelity |
| Baxter Healthcare | $112.44 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Gilead Sciences, INC. | $109.68 | 2021-2022 | |
| Csl Behring | $93.82 | 2022 | |
| Daiichi Sankyo INC. | $69.18 | 2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $63.69 | 2022-2023 | |
| Advanced Respiratory, INC | $55.27 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.74 | 2022-2023 | Glassia |
| Sandoz INC. | $54.20 | 2023 | Treprostinil |
| Mylan Specialty L.P. | $49.57 | 2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $46.44 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $43.69 | 2021 | |
| Electromed, INC. | $43.33 | 2023 | Smartvest |
| Sunovion Pharmaceuticals INC. | $40.35 | 2021 | |
| Mallinckrodt Hospital Products INC. | $37.89 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $36.39 | 2023 | |
| Merck Sharp & Dohme LLC | $28.72 | 2023 | |
| Cmp Pharma, INC. | $28.72 | 2023 | Tadliq |
| Boston Scientific Corporation | $15.67 | 2021 | |
| Mayne Pharma Commercial LLC | $15.55 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.45 | 2022 | |
| Pulmonx Corporation | $14.53 | 2023 | Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Janssen Pharmaceuticals, INC | $13.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Overton-Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.